Meeting
2022 ASCO Annual Meeting
Comprehensive transcriptomic analysis of immune checkpoint markers in a pancancer cohort: Implications for response and resistance.
Authors
Hirotaka Miyashita
Mount Sinai Beth Israel, New York, NY
Hirotaka Miyashita , Nicholas J. Bevins , Kartheeswaran Thangathurai , Suzanna Lee , Sarabjot Pabla , Mary Nesline , Sean Glenn , Jeffrey M. Conroy , Paul DePietro , Eitan Rubin , Jason K. Sicklick , Shumei Kato , Razelle Kurzrock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immunobiology
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2555)
DOI
10.1200/JCO.2022.40.16_suppl.2555
Abstract #
2555
Poster Bd #
210
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC).
First Author: Aakash Desai
Poster
2020 ASCO Virtual Scientific Program
Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities.
First Author: Jacob J. Adashek
Poster
2017 ASCO Annual Meeting
Evaluating the repertoire of immune checkpoint markers expressed on peripheral and ascites CD8+ T cells in ovarian cancer.
First Author: Stephanie Gaillard
Poster
2016 ASCO Annual Meeting
Association of methylation of homologous repair genes with expression of immune checkpoints in squamous cell carcinoma of head and neck, lung and cervix.
First Author: Damian Tobias Rieke